pheochromocytoma
Information
- Disease name
- pheochromocytoma
- Disease ID
- DOID:0050771
- Description
- "An endocrine organ benign neoplasm that arises within the adrenal medulla, releasing epinephrines and norepinephrines hormones that cause either episodic or persistent high blood pressure." [url:https\://en.wikipedia.org/wiki/Pheochromocytoma, url:https\://rarediseases.info.nih.gov/diseases/7385/pheochromocytoma, url:https\://www.mayoclinic.org/diseases-conditions/pheochromocytoma/symptoms-causes/syc-20355367, url:https\://www.omim.org/entry/171300]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04400474 | Active, not recruiting | Phase 2 | Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study | October 7, 2020 | March 2024 |
| NCT05446779 | Active, not recruiting | Postmortem Evaluation of Adrenal and Other Endocrine Tumors in Patients With Sudden Death | February 3, 2022 | December 31, 2026 | |
| NCT04711135 | Active, not recruiting | Phase 2 | Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs | August 31, 2022 | May 7, 2029 |
| NCT04187404 | Active, not recruiting | Phase 1/Phase 2 | A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma | July 23, 2020 | November 30, 2025 |
| NCT01377532 | Approved for marketing | Compassionate Use of 131I-MIBG for Patients With Malignant Pheochromocytoma | |||
| NCT02961491 | Approved for marketing | Expanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma | |||
| NCT03015844 | Available | A Compassionate Use/Expanded Access Protocol Using 131I-MIBG Therapy for Patients With Refractory Neuroblastoma and Metastatic Pheochromocytoma | |||
| NCT01590680 | Available | Expanded Access Protocol Using 131I-MIBG | |||
| NCT05082311 | Completed | Cardiac and Vascular Changes in Pheochromocytoma and Paraganglioma | January 19, 2019 | January 31, 2022 | |
| NCT00126412 | Completed | Phase 3 | Meta-Iodobenzylguanidine (123I mIBG) Scintigraphy in Patients Being Evaluated for Phaeochromocytoma or Neuroblastoma | August 2, 2005 | September 27, 2006 |
| NCT00188019 | Completed | N/A | Hereditary Paraganglioma: Evaluation of Screening Methods to Detect Tumors in SDH Positive Carriers | November 2005 | November 2013 |
| NCT00339131 | Completed | Phase 1 | ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic Carcinoid | June 2006 | January 2007 |
| NCT00458952 | Completed | Phase 1/Phase 2 | Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma | April 2007 | June 2011 |
| NCT00590096 | Completed | I-123-MIBG for Imaging of Neuroblastoma and Pheochromocytoma | January 1991 | December 2008 | |
| NCT04566406 | Completed | Pheochromocytoma and Hemodynamic Instability | January 2003 | September 2020 | |
| NCT00843037 | Completed | Phase 2 | Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma | February 2009 | March 14, 2022 |
| NCT04557072 | Completed | Selective Versus Nonselective Alpha-blockade Prior to Pheochromocytoma Resection - Systematic Review and Meta-analysis | August 1, 2020 | November 2, 2020 | |
| NCT00923481 | Completed | Phase 2 | A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H... | April 2009 | January 2012 |
| NCT00970970 | Completed | Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau Disease | September 2009 | November 2012 | |
| NCT01022515 | Completed | Specificity of Elevated Plasma EM66 Levels in Pheochromocytoma | November 2008 | December 2013 | |
| NCT01152827 | Completed | Phase 2 | RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid | July 2008 | December 2011 |
| NCT04320589 | Completed | Phase 2 | the Effect of Dexmedetomidine and Magnesium Sulfate in Open Resection of Pheochromocytoma | June 30, 2019 | August 30, 2021 |
| NCT01379898 | Completed | Phase 4 | Phenoxybenzamine Versus Doxazosin in PCC Patients | December 2011 | January 2018 |
| NCT01413503 | Completed | Phase 2 | A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors | May 1991 | May 2009 |
| NCT01425710 | Completed | Non-invasive Evaluation of Fluid Status and Cardiac Output During Operative Treatment of Pheochromcytoma | August 2011 | July 2013 | |
| NCT00001229 | Completed | Diagnosis and Treatment of Pheochromocytoma | October 1988 | January 2001 | |
| NCT01949714 | Completed | Effect of Chronic Catecholamine Overproduction on Brown Adipose Tissue | August 2013 | January 2022 | |
| NCT01959711 | Completed | Phase 4 | Randomized Clinical Trial of Posterior Retroperitoneoscopic Adrenalectomy Versus Lateral Laparoscopic Adrenalectomy | January 2006 | July 2013 |
| NCT01967576 | Completed | Phase 2 | Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma | October 19, 2013 | December 1, 2020 |
| NCT00001147 | Completed | Blood Sampling for Neurochemical and Genetic Testing | October 1999 | March 2004 | |
| NCT02618694 | Completed | N/A | Efficacy and Safety of Posterior Retroperitoneoscopic Adrenalectomy: A Comparative Study | April 2015 | December 2016 |
| NCT04071561 | Completed | Prevention of Conversion in Posterior Retroperitoneal Adrenalectomy by Measuring Preoperative Anatomical Conditions | November 19, 2018 | May 31, 2019 | |
| NCT03176693 | Completed | Phase 3 | Preoperative Alpha Blockade for Pheochromocytoma | May 5, 2017 | October 10, 2021 |
| NCT00002608 | Completed | Phase 2 | Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors | May 1994 | April 2005 |
| NCT00002641 | Completed | Phase 3 | Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma | February 1995 | June 2012 |
| NCT00002764 | Completed | Phase 3 | Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma | April 1996 | |
| NCT06037135 | Completed | N/A | Dexmedetomidine Infusion During Laparoscopic Adrenalectomy | December 3, 2012 | March 26, 2021 |
| NCT00028106 | Completed | Phase 2 | 131MIBG to Treat Malignant Pheochromocytoma | December 5, 2001 | January 8, 2007 |
| NCT00049023 | Completed | Phase 1 | Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors | January 2002 | August 2011 |
| NCT03474237 | Enrolling by invitation | A Prospective Cohort Study for Patients With Adrenal Diseases | October 1, 2018 | December 31, 2027 | |
| NCT02431715 | No longer available | 18F-FDOPA PET in Neuroendocrine Tumours | |||
| NCT01838187 | No longer available | Expanded Access Protocol Using 131I-MIBG Therapy +/- Vorinostat for Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma | |||
| NCT06427798 | Not yet recruiting | Phase 1/Phase 2 | Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy | June 23, 2024 | July 1, 2039 |
| NCT06444607 | Not yet recruiting | Hereditary Pheochromocytoma Assessment of Tumour Immunologies | June 1, 2024 | June 1, 2029 | |
| NCT04788927 | Not yet recruiting | Development of a Predictive Model for the Risk of Metastatic Disease in PPGLs, a Retrospective Cohort Study | October 1, 2023 | September 30, 2027 | |
| NCT06233903 | Not yet recruiting | Phase 2 | 18F-mFBG Expression in Neural Crest Tumors and Organs Innervated by the Sympathetic Nervous System | July 2024 | March 2025 |
| NCT06377033 | Not yet recruiting | N/A | Using the EHR to Advance Genomic Medicine Across a Diverse Health System | May 1, 2024 | June 30, 2027 |
| NCT06045260 | Not yet recruiting | Phase 2 | "Receptor Radionuclide Therapy With 177Lu-DOTATOC | October 2023 | January 2027 |
| NCT03160274 | Recruiting | Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions | October 19, 2005 | December 31, 2030 | |
| NCT04119024 | Recruiting | Phase 1 | Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors | November 27, 2019 | October 1, 2025 |
| NCT03344016 | Recruiting | N/A | Multicenter Pheochromocytoma and Paraganglioma Evaluation | November 1, 2017 | November 1, 2040 |
| NCT06440122 | Recruiting | The Incidence and Outcomes of Metabolically Active Brown Adipose Tissue (aBAT) in Patients With Pheochromocytoma or Paraganglioma (PPGLs) | May 31, 2024 | December 31, 2024 | |
| NCT03541720 | Recruiting | Early Phase 1 | 18F-Fluorodopamine PET Studies of Neuroblastoma and Pheochromocytoma | April 30, 2019 | July 1, 2026 |
| NCT00669266 | Recruiting | Adrenal Tumors - Pathogenesis and Therapy | September 2002 | December 2030 | |
| NCT03583528 | Recruiting | DOTATOC PET/CT for Imaging NET Patients | July 11, 2018 | December 31, 2028 | |
| NCT06050057 | Recruiting | Surgical Treatment of Adrenal Diseases- Laparoscopic vs. Robotic-assisted Adrenalectomy | September 3, 2023 | June 30, 2026 | |
| NCT06062082 | Recruiting | Intraoperative Hemodynamic Instability During Unilateral Adrenalectomy for Pheochromocytoma | September 1, 2015 | September 1, 2024 | |
| NCT06229405 | Recruiting | Development of Clinical Evidence for Optimal Management of Adrenal Diseases Based on Real-World Data | May 10, 2022 | December 31, 2024 | |
| NCT06429397 | Recruiting | Phase 2 | First-line Anlotinib Combined With Penpulimab for Advanced Pheochromocytoma: A Single-arm, Multicenter, Prospective Phase II Study | May 15, 2024 | May 28, 2026 |
| NCT03946527 | Recruiting | Phase 2 | LAnreotide in Metastatic Pheochromocytoma / PARAganglioma (LAMPARA) | June 17, 2019 | December 2023 |
| NCT04028479 | Recruiting | The Registry of Oncology Outcomes Associated With Testing and Treatment | May 5, 2021 | October 1, 2031 | |
| NCT00107289 | Recruiting | Phase 2 | Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma | May 2006 | May 2025 |
| NCT05158712 | Recruiting | Genetic Factors and Pheochromocytomas in Neoplasia Type 2 | February 2, 2022 | December 14, 2023 | |
| NCT00004847 | Recruiting | Phase 1 | Diagnosis of Pheochromocytoma | March 22, 2000 | November 30, 2048 |
| NCT05636540 | Recruiting | Early Phase 1 | In Vivo PARP-1 Expression With 18F-FluorThanatrace PET/CT in Patients With Pheochromocytoma and Paraganglioma | July 1, 2023 | December 31, 2025 |
| NCT05636618 | Recruiting | Phase 1/Phase 2 | Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors | September 27, 2023 | January 31, 2028 |
| NCT05702944 | Recruiting | Phase 4 | The Effect and Safety of Omitting Preoperative Alpha-adrenergic Blockade for Normotensive Pheochromocytoma | January 18, 2023 | October 31, 2024 |
| NCT05883085 | Recruiting | Phase 2 | A Study on the Safety and Effectiveness of Anlotinib for Neoadjuvant Treatment of PPGL | May 1, 2022 | May 1, 2024 |
| NCT05885386 | Recruiting | Phase 2 | A Study on the Safety and Effectiveness of Temozolomide for Neoadjuvant Treatment of PPGL | April 1, 2023 | October 1, 2025 |
| NCT04890444 | Recruiting | China Adrenal Disease Registry | June 1, 2021 | April 30, 2026 | |
| NCT03839498 | Recruiting | Phase 2 | Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Pheochromocytoma/Paraganglioma | January 22, 2019 | January 2024 |
| NCT03206060 | Recruiting | Phase 2 | Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma | October 10, 2017 | January 1, 2027 |
| NCT05069220 | Recruiting | Early Phase 1 | 18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor | September 1, 2021 | December 2026 |
| NCT04605848 | Terminated | N/A | Infrared Thermography Associated With Cutaneous Microcirculation for Detection of Brown-adipose Tissue (MICROBAT) | July 3, 2020 | October 20, 2023 |
| NCT00466856 | Terminated | Phase 2 | Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors | December 2003 | October 2007 |
| NCT00911729 | Terminated | Content Validation of Quality of Life and Symptom Questionnaires for Pheochromocytoma and Paraganglioma | April 2009 | ||
| NCT03986593 | Terminated | N/A | Cryoablation of Bone Metastases From Endocrine Tumors | September 26, 2019 | May 29, 2023 |
| NCT05948137 | Terminated | F-18 FDOPA PET/CT Versus I-123 MIBG Scintigraphy With SPECT/CT for the Diagnosis of Pheochromocytoma and Paraganglioma | September 21, 2017 | June 30, 2020 | |
| NCT03165721 | Terminated | Phase 2 | A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer | August 16, 2017 | February 24, 2020 |
| NCT05456997 | Terminated | Metabolic Myopathy in Endocrinopathy | March 20, 2023 | September 30, 2023 | |
| NCT00002947 | Terminated | Phase 1 | Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer | October 1996 | August 2004 |
| NCT05053685 | Unknown status | Metanephrines in Obstructive Sleep Apnoea | July 29, 2020 | December 1, 2021 | |
| NCT03158870 | Unknown status | Surgeon-Anesthesiologist Collaboration | July 2017 | December 2017 | |
| NCT01373736 | Unknown status | Phase 3 | 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors | ||
| NCT00874614 | Unknown status | Phase 2 | A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma | June 4, 2009 | February 2021 |
| NCT04573816 | Unknown status | Development of a Tele-monitoring Program for Patients Undergoing Surgery for Pheochromocytoma and / or Paraganglioma | October 8, 2020 | November 1, 2023 | |
| NCT04891081 | Unknown status | Plasma Metanephrines in Patients With Cyanotic and Acyanotic Congenital Heart Disease | November 1, 2019 | June 9, 2021 | |
| NCT05451134 | Unknown status | Predictors and Outcomes of Dysglycemia in Pheochromocytoma and Paraganglioma | June 30, 2022 | July 20, 2022 | |
| NCT04276597 | Withdrawn | Phase 2 | Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET. | March 4, 2020 | July 15, 2021 |
| NCT03923257 | Withdrawn | Phase 1/Phase 2 | Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents | August 4, 2020 | June 3, 2021 |
- Disase is a (Disease Ontology)
- DOID:0060089
- Cross Reference ID (Disease Ontology)
- GARD:7385
- Cross Reference ID (Disease Ontology)
- ICDO:8700/3
- Cross Reference ID (Disease Ontology)
- MESH:D010673
- Cross Reference ID (Disease Ontology)
- MIM:171300
- Exact Synonym (Disease Ontology)
- phaeochromocytoma
- HPO Human Phenotype ID (Human Phenotype Ontology)
- HP:0002666
- MeSH unique ID (MeSH (Medical Subject Headings))
- D010673